I totally agree that the second paragraph should be different and more personalized, including the phrase from hgen PR "...unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19".
I was just saying, that we must have received the same boilerplate end. It's frustrating, that they use this same language (provide us more data) for other drugs that for sure have more risks than benefits for covid.
Market Data 
Markets 
AI
